United Therapeutics Corporation (UTHR) was Reiterated by RBC Capital Mkts to “Sector Perform” while Lowering the Price Target of the company shares to $ 122 from a previous price target of $150 . RBC Capital Mkts advised their investors in a research report released on Apr 11, 2016.
Many Wall Street Analysts have commented on United Therapeutics Corporation. Shares were Reiterated by Wedbush on Mar 28, 2016 to “Outperform” and Lowered the Price Target to $ 229 from a previous price target of $238 .Shares were Reiterated by Wedbush on Mar 2, 2016 to “Outperform” and Lowered the Price Target to $ 238 from a previous price target of $244 .Standpoint Research Upgraded United Therapeutics Corporation on Feb 10, 2016 to ” Buy”, Price Target of the shares are set at $148.
On the company’s financial health, United Therapeutics Corporation reported $3.68 EPS for the quarter, beating the analyst consensus estimate by $ 0.87 according to the earnings call on Feb 25, 2016. Analyst had a consensus of $2.81. The company had revenue of $404.90 million for the quarter, compared to analysts expectations of $385.51 million. The company’s revenue was up 16.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted $3.21 EPS.
United Therapeutics Corporation closed down -3.13 points or -2.77% at $109.81 with 7,73,177 shares getting traded on Monday. Post opening the session at $112.4, the shares hit an intraday low of $108.31 and an intraday high of $112.4 and the price fluctuated in this range throughout the day.Shares ended Monday session in Red.
In a different news, on Apr 8, 2016, Martine A Rothblatt (Chairman & Co-CEO) sold 5,546 shares at $114.15 per share price. According to the SEC, on Apr 4, 2016, Raymond Dwek (director) sold 3,000 shares at $110.79 per share price. On Mar 3, 2016, Tommy G Thompson (director) sold 3,000 shares at $126.54 per share price, according to the Form-4 filing with the securities and exchange commission.
United Therapeutics Corporation is a biotechnology company. The Company is focused on the development and commercialization of products for the treatment of chronic and life-threatening conditions. The Companys key therapeutic products and product candidates include Remodulin Tyvaso (treprostinil) Adcirca (tadalafil) Remodulin Implantable System Orenitram Combination Therapy Esuberaprost and PLX Cells for the treatment of Pulmonary Arterial Hypertension; Ch14.18 MAb for the treatment of High-risk neuroblastoma; Ex-Vivo Lung Perfusion and Lung Transplantation for the treatment of End-stage lung disease; UV-4B for the treatment of Dengue and influenza and Glycobiology Antiviral Agents for the treatment of a spectrum of agents against viral infectious diseases among others. The Companys lead product for treating Pulmonary Arterial Hypertension (PAH) is Remodulin.